The math transform module provides an execution environment for Inverse Tangent Over Price Movement transformation and related indicators on Oragenics. Signals here center on price transformations that reveal shifts in trend structure alongside volatility and performance references.
The output start index for this execution was zero with a total number of output elements of sixty-one. Oragenics Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Oragenics price patterns.
Oragenics Technical Analysis Modules
Most technical analysis of Oragenics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Oragenics from various momentum indicators to cycle indicators. When you analyze Oragenics charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. Oragenics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 5 people. The profile for Oragenics integrates fundamentals, price behavior, and sector exposure. Price behavior may show elevated responsiveness to broader market cycles. Oragenics has a market cap of 3.69 M, ROE of -1.69%.
Methodology
Unless otherwise specified, financial data for Oragenics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Oragenics (USA Stocks:OGEN) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Oragenics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Oragenics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
A structured review of Oragenics often starts with core financial statements and trend context. Ratios and trend metrics help frame Oragenics' operating context. Key reports that frame Oragenics Stock are listed below:
Oragenics has a market cap of 3.69 M, ROE of -1.69%. Use Your Equity Center to explore allocation context. This includes a position in Oragenics in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued.
To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.Analysis related to Oragenics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Earnings Share
48.21
Quarterly Revenue Growth
-0.91
Return On Assets
-0.71
Return On Equity
-1.69
The market value of Oragenics is measured differently than book value, which reflects Oragenics accounting equity. Oragenics' market capitalization is 3.69 M. A P/B ratio of 0.41 suggests Oragenics trades near or below book value. Value and price for Oragenics are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
Note that Oragenics' intrinsic value and market price are different measures derived from different inputs. For Oragenics, key inputs include a P/B ratio of 0.41, and ROE of -1.69%. Market price reflects the current exchange level formed by active bids and offers.